Molecular diagnosis in breast cancer

Diagnostic Histopathology

Volumn 14, Issue 5, 2008, Pages 202-213

  Marchiò, Caterina ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

chromogenic in situ hybridization; fluorescence in situ hybridization; microarrays; molecular profiling; prediction; prognosis; therapeutic target

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER RISK; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYBRIDIZATION; IN SITU HYBRIDIZATION; MICROARRAY ANALYSIS; PREDICTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

EID: 45349108775     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2008.03.002     Document Type: Article

References (76)

1. Reis-Filho J.S., Westbury C., and Pierga J.Y. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 59 (2006) 225-231
2. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
3. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
4. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003) 8418-8423
5. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
6. Brenton J.D., Carey L.A., Ahmed A.A., and Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 23 (2005) 7350-7360
7. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7 (2006) 96
8. Perreard L., Fan C., Quackenbush J.F., et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8 (2006) R23
9. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
10. Teschendorff A.E., Miremadi A., Pinder S.E., Ellis I.O., and Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8 (2007) R157
11. Farmer P., Bonnefoi H., Becette V., et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 (2005) 4660-4671
12. Bergamaschi A., Kim Y.H., Wang P., et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45 (2006) 1033-1040
13. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
14. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
15. Galea M.H., Blamey R.W., Elston C.E., and Ellis I.O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22 (1992) 207-219
16. Eifel P., Axelson J.A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93 (2001) 979-989
17. He Y.D., and Friend S.H. Microarrays-the 21st century divining rod?. Nat Med 7 (2001) 658-659
18. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
19. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
20. Ioannidis J.P. Microarrays and molecular research: noise discovery?. Lancet 365 (2005) 454-455
21. Michiels S., Koscielny S., and Hill C. Interpretation of microarray data in cancer. Br J Cancer 96 (2007) 1155-1158
22. Simon R., Radmacher M.D., Dobbin K., and McShane L.M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 (2003) 14-18
23. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23 (2005) 7332-7341
24. Sotiriou C., and Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 7 (2007) 545-553
25. Shi L., Reid L.H., Jones W.D., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24 (2006) 1151-1161
26. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
27. Pusztai L., Cristofanilli M., and Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin Oncol 34 (2007) S10-S16
28. Esteva F.J., Sahin A.A., Cristofanilli M., et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11 (2005) 3315-3319
29. Mina L., Soule S.E., Badve S., et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 103 (2007) 197-208
30. Buerger H., Mommers E.C., Littmann R., et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194 (2001) 165-170
31. Roylance R., Gorman P., Harris W., et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 59 (1999) 1433-1436
32. Simpson P.T., Reis-Filho J.S., Gale T., and Lakhani S.R. Molecular evolution of breast cancer. J Pathol 205 (2005) 248-254
33. Cleton-Jansen A.M., Buerger H., Haar N., et al. Different mechanisms of chromosome 16 loss of heterozygosity in well-versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 41 (2004) 109-116
34. Reis-Filho J.S., Simpson P.T., Gale T., and Lakhani S.R. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract 201 (2005) 713-725
35. Ma X.J., Salunga R., Tuggle J.T., et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100 (2003) 5974-5979
36. Robbins P., Pinder S., de Klerk N., et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26 (1995) 873-879
37. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
38. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
39. Ivshina A.V., George J., Senko O., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66 (2006) 10292-10301
40. Habel L.A., Shak S., Jacobs M.K., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8 (2006) R25
41. Lambros M.B., Natrajan R., and Reis-Filho J.S. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 38 (2007) 1105-1122
42. Hicks D.G., and Tubbs R.R. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36 (2005) 250-261
43. Holst F., Stahl P.R., Ruiz C., et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39 (2007) 655-660
44. Tognon C., Knezevich S.R., Huntsman D., et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2 (2002) 367-376
45. Rosen P.P., and Cranor M.L. Secretory carcinoma of the breast. Arch Pathol Lab Med 115 (1991) 141-144
46. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
47. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
48. Pauletti G., Godolphin W., Press M.F., and Slamon D.J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13 (1996) 63-72
49. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
50. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
51. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
52. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
53. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357 (2007) 39-51
54. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
55. Wolff A.C., Hammond M., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
56. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19 (2001) 2587-2595
57. Nahta R., and Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 26 (2007) 3637-3643
58. Reis-Filho J.S., Pinheiro C., Lambros M.B., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209 (2006) 445-453
59. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
60. Hoadley K.A., Weigman V.J., Fan C., et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8 (2007) 258
61. Reis-Filho J.S., Simpson P.T., Turner N.C., et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12 (2006) 6652-6662
62. Elbauomy Elsheikh S., Green A.R., Lambros M.B., et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9 (2007) R23
63. Eccles D.M., and Pichert G. Familial non-BRCA1/BRCA2-associated breast cancer. Lancet Oncol 6 (2005) 705-711
64. Honrado E., Benitez J., and Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18 (2005) 1305-1320
65. Farshid G., Balleine R.L., Cummings M., and Waring P. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol 30 (2006) 1357-1366
66. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 (1998) 1138-1145
67. Lakhani S.R., van de Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20 (2002) 2310-2318
68. Turner N.C., and Reis-Filho J.S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25 (2006) 5846-5853
69. Bane A.L., Beck J.C., Bleiweiss I., et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31 (2007) 121-128
70. Turner N.C., Reis-Filho J.S., Russell A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2007) 2126-2132
71. Lakhani S.R., Reis-Filho J.S., Fulford L., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11 (2005) 5175-5180
72. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
73. Yap T.A., Boss D.S., Fong P.C., et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol 25 (2007) 3529
74. Rosai J. Why microscopy will remain a cornerstone of surgical pathology. Lab Invest 87 (2007) 403-408
75. Tischkowitz M., Xia B., Sabbaghian N., et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104 (2007) 6788-6793
76. Balleine R.L., Murali R., Bilous A.M., et al. Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology 49 (2006) 523-532